Overview

Trial of DA-EPOCH Regimen for NHL With HLH

Status:
Unknown status
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
The major purpose of this clinical study is to assess clinical outcome of dose-adjusted EPOCH regimen for patients with non-Hodgkin's lymphoma(NHL)-associated hemophagocytic lymphohistiocytosis
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Treatments:
Cyclophosphamide
Doxorubicin
Etoposide
Prednisone
Rituximab
Vincristine